Table 3.
In‐Hospital Medications and Revascularization Procedures
| Acute treatments | T1MI, n=379 | T2MI, n=62 | P value |
|---|---|---|---|
| Thrombolysis | 40 (10.5) | 9 (14.5) | 0.357 |
| PCI | 168 (44.3) | 12 (19.3) | <0.001 |
| Aspirin | 356 (93.9) | 54 (87.1) | 0.061 |
| P2Y12 inhibitors | 345 (91.0) | 45 (72.6) | <0.001 |
| Unfractioned heparin | 28 (7.4) | 13 (21.0) | <0.001 |
| LMWH | 308 (81.3) | 40 (64.5) | 0.002 |
| β‐Blockers | 273 (72.0) | 40 (64.5) | 0.226 |
| Statins | 287 (75.7) | 45 (72.6) | 0.594 |
| ACEI/ARB | 271 (71.5) | 44 (71.0) | 0.931 |
| Diuretics | 96 (25.3) | 20 (32.2) | 0.250 |
| DOA | 0 (0) | 1 (1.6) | 0.140 |
| VKA | 0 (0) | 5 (8.1) | <0.001 |
Values are expressed as number (percentage). ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin 2 receptor blocker; DOA, direct oral anticoagulant; LMWH, low‐molecular‐weight heparin; PCI, percutaneous coronary intervention; T1MI, type 1 myocardial infarction; T2MI, type 2 myocardial infarction; and VKA, vitamin K antagonist.